
WGS Stock Forecast & Price Target
WGS Analyst Ratings
Bulls say
GeneDx Holdings Corp has demonstrated a solid performance, with total revenue reaching $87.1 million, reflecting a significant 42% year-over-year growth, which surpassed consensus expectations by approximately 9%. The company is positioned for substantial growth with projected volume increases of around 30% year-over-year in Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS), alongside a notable 62% year-over-year revenue increase in these areas. Strategic improvements in reimbursement processes, cost synergies through automation, and a robust data advantage in rare diseases are expected to contribute to GeneDx's long-term value and success in the evolving precision medicine landscape.
Bears say
GeneDx Holdings Corp has experienced a concerning decline in 1Q whole exome sequencing (WES) and whole genome sequencing (WGS) volumes, which fell 1% quarter-over-quarter despite a year-over-year increase of 24%. Following a first-quarter earnings beat that did not meet elevated investor expectations, the company's stock saw a significant decline of approximately 43%. Analysts have lowered the price target, reflecting heightened risks associated with slower-than-expected growth in testing volumes, competitive pressures, and potential obstacles in health system partnerships and reimbursement challenges.
This aggregate rating is based on analysts' research of GeneDx Holdings Corp and is not a guaranteed prediction by Public.com or investment advice.
WGS Analyst Forecast & Price Prediction
Start investing in WGS
Order type
Buy in
Order amount
Est. shares
0 shares